Gilead HIV

Gilead Sciences is a leading biopharmaceutical company committed to ending the HIV epidemic through innovative science, community activism, and educational initiatives. Since the dawn of the HIV crisis, Gilead has pioneered advancements in treatment, developing therapies that simplify medication regimens and launching pre-exposure prophylaxis (PrEP) to prevent HIV transmission. Their comprehensive approach not only focuses on effective treatments but also addresses systemic barriers that impact access to care, collaborating with community organizations to create equitable healthcare solutions.

Central to Gilead's mission is the Gilead Advancing Access® program, offering resources and financial support to ensure that both insured and uninsured individuals can access HIV medications at no cost. They have provided millions in grants to organizations dedicated to supporting marginalized communities affected by HIV.

In addition to their therapeutic innovations, Gilead emphasizes the importance of education and advocacy, implementing initiatives like the Blueprints for Success Training Institutes, aimed at equipping leaders with essential knowledge. Through strategic partnerships and ongoing research, Gilead strives to improve the lives of those impacted by HIV worldwide.